This information is intended for patients prescribed apixaban in UK only.


If you have a VTE, your chance of having a recurrence is higher than someone who has never had one.

The risk of recurrence is:

  • About 3% a year in people who no longer have risk factors for VTE (e.g. have recovered from surgery or who no longer travel long-haul)
  • About 10% a year or more, in people who still have risk factors (e.g. cancer or inherited disorder) or whose cause of VTE was unknown.

The risk of recurrence will vary for each person based upon individual risk factors.

As early detection is important for reducing risk, recognising the signs and symptoms of a new or recurrent VTE and getting prompt treatment are vital.

Blue information icon

Patients prescribed apixaban

This section is intended for patients prescribed apixaban in the UK to provide information on this medicine, and its uses. It is not intended to replace in any way the opinion of a healthcare professional. For specific information about the pathology and/or detection, diagnosis, prognosis, administration and, where applicable, appropriate treatment for each specific case, please promptly consult a healthcare professional. The use of this website is subject to the legal notice, the privacy and cookie policy, the pharmacovigilance notice (if appropriate) and the applicable laws and regulations.

Report Side Effects

If you experience any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at

Side effects for this medicine should also be reported to Bristol-Myers Squibb Medical Information on 0800 731 1736 or